Recurrent epithelial ovarian cancer: an update on treatment

Oncology (Williston Park). 2013 Apr;27(4):288-94, 298.


An estimated 85% of patients with epithelial ovarian cancer who achieve a full remission following first-line therapy will develop recurrent disease. Although each subsequent line of therapy is characterized by shorter disease-free intervals, median survival for these patients ranges from 12 months to 24 months. Emerging therapies in the management of ovarian cancer have resulted in a shift in paradigm, including in the appropriate time to institute therapy, and in the selection of therapy. This review focuses on chemotherapy and emerging biologic agents that present a therapeutic option for patients with recurrent ovarian cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Ovarian Epithelial
  • Doxorubicin / analogs & derivatives
  • Doxorubicin / therapeutic use
  • Female
  • Guanidines / administration & dosage
  • Humans
  • Neoplasm Recurrence, Local / drug therapy*
  • Neoplasms, Glandular and Epithelial / drug therapy*
  • Ovarian Neoplasms / drug therapy*
  • Polyethylene Glycols / therapeutic use
  • Time Factors


  • Guanidines
  • liposomal doxorubicin
  • gemedine
  • Polyethylene Glycols
  • Doxorubicin